Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study.


Journal

The British journal of psychiatry : the journal of mental science
ISSN: 1472-1465
Titre abrégé: Br J Psychiatry
Pays: England
ID NLM: 0342367

Informations de publication

Date de publication:
12 2019
Historique:
pubmed: 28 7 2019
medline: 4 8 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

The first episode of psychosis is a critical period in the emergence of cardiometabolic risk. We set out to explore the influence of individual and lifestyle factors on cardiometabolic outcomes in early psychosis. This was a prospective cohort study of 293 UK adults presenting with first-episode psychosis investigating the influence of sociodemographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use) and medication on cardiometabolic outcomes over the following 12 months. Rates of obesity and glucose dysregulation rose from 17.8% and 12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 h daily. We found no association between lifestyle at baseline or type of antipsychotic medication prescribed with either baseline or 1-year cardiometabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their White counterparts. At 12 months, one-third of those with BME heritage exceeded the threshold for prediabetes (HbA1c >39 mmol/mol). Unhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence, however, that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow for differential patterns of emergence of cardiometabolic risk in people of different ethnicities.

Sections du résumé

BACKGROUND
The first episode of psychosis is a critical period in the emergence of cardiometabolic risk.
AIMS
We set out to explore the influence of individual and lifestyle factors on cardiometabolic outcomes in early psychosis.
METHOD
This was a prospective cohort study of 293 UK adults presenting with first-episode psychosis investigating the influence of sociodemographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use) and medication on cardiometabolic outcomes over the following 12 months.
RESULTS
Rates of obesity and glucose dysregulation rose from 17.8% and 12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 h daily. We found no association between lifestyle at baseline or type of antipsychotic medication prescribed with either baseline or 1-year cardiometabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their White counterparts. At 12 months, one-third of those with BME heritage exceeded the threshold for prediabetes (HbA1c >39 mmol/mol).
CONCLUSIONS
Unhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence, however, that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow for differential patterns of emergence of cardiometabolic risk in people of different ethnicities.

Identifiants

pubmed: 31347480
pii: S0007125019001594
doi: 10.1192/bjp.2019.159
pmc: PMC7557635
doi:

Substances chimiques

Antipsychotic Agents 0
Glycated Hemoglobin A 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

712-719

Subventions

Organisme : Medical Research Council
ID : MR/N027078/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L022176/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U120097115
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0700995
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CL-2017-03-001
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom

Références

Lancet Psychiatry. 2017 Jul;4(7):540-546
pubmed: 28624180
Br J Psychiatry. 2012 Dec;201(6):481-5
pubmed: 22955007
Comput Stat Data Anal. 2010 Oct 1;54(10):2267-2275
pubmed: 24748700
Am J Epidemiol. 2009 May 1;169(9):1133-9
pubmed: 19318618
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Trials. 2016 Dec 12;17(1):594
pubmed: 27955680
Lancet Psychiatry. 2017 May;4(5):389-399
pubmed: 28330589
Addict Behav. 1978;3(3-4):235-41
pubmed: 735910
Obes Rev. 2017 Jul;18(7):715-723
pubmed: 28489290
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
Schizophr Bull. 2010 Jan;36(1):71-93
pubmed: 19955390
Psychosomatics. 1995 May-Jun;36(3):267-75
pubmed: 7638314
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
Schizophr Res. 2016 Mar;171(1-3):103-9
pubmed: 26805414
Schizophr Res. 1990 Jul-Aug;3(4):247-51
pubmed: 2278986
Psychol Med. 2015;45(12):2619-29
pubmed: 25961431
Am J Psychiatry. 2004 Feb;161(2):361-3
pubmed: 14754788
JAMA Psychiatry. 2017 Mar 1;74(3):261-269
pubmed: 28097367
Early Interv Psychiatry. 2016 Jun;10(3):193-202
pubmed: 25962699
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
JAMA Psychiatry. 2015 Dec;72(12):1172-81
pubmed: 26509694
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Schizophr Bull. 2014 Jul;40(4):796-803
pubmed: 23943410
Psychopathology. 2006;39(4):175-8
pubmed: 16636640
Lancet Psychiatry. 2019 May;6(5):379-390
pubmed: 30975539
Fam Pract. 1994 Dec;11(4):375-81
pubmed: 7895964
Diabet Med. 2017 Jul;34(7):916-924
pubmed: 27973692
Br J Psychiatry. 1996 Jul;169(1):58-63
pubmed: 8818369
BMJ Open. 2014 Feb 06;4(2):e004138
pubmed: 24503301
Diabetes Care. 2011 Jul;34(7):1492-6
pubmed: 21602429
Arch Intern Med. 1992 Jun;152(6):1257-62
pubmed: 1599355
Schizophr Res. 2015 Oct;168(1-2):381-7
pubmed: 26278336
Schizophr Res. 2015 Oct;168(1-2):461-4
pubmed: 26189077
Int J Neuropsychopharmacol. 2013 Jun;16(5):987-95
pubmed: 23253821
Schizophr Res. 2006 Feb 28;82(2-3):225-31
pubmed: 16360305
Psychol Med. 2016 Nov;46(15):3231-3240
pubmed: 27605254
Schizophr Res. 2016 Feb;170(2-3):311-7
pubmed: 26718334
Br J Psychiatry. 2009 Dec;195(6):488-91
pubmed: 19949195
Early Interv Psychiatry. 2016 Jun;10(3):267-76
pubmed: 25721464

Auteurs

Fiona Gaughran (F)

Lead Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS Foundation Trust; and Reader, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, Denmark Hill, UK.

Daniel Stahl (D)

Professor in Medical Statistics and Statistical Learning, Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

Dominic Stringer (D)

Statistician, Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

David Hopkins (D)

Consultant Diabetologist, Institute Director and Clinical Academic Group Lead, Institute of Diabetes, Endocrinology and Obesity, King's Health Partners, UK.

Zerrin Atakan (Z)

Senior Lecturer, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

Kathryn Greenwood (K)

Professor of Clinical Psychology, School of Psychology, University of Sussex, UK.

Anita Patel (A)

Director, Anita Patel Health Economics Consulting Ltd; and Honorary Professor, Queen Mary University of London, UK.

Shubulade Smith (S)

Clinical Senior Lecturer, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; and Consultant Psychiatrist, Forensic Services, South London and Maudsley NHS Foundation Trust, UK.

Poonam Gardner-Sood (P)

Clinical Trials Manager, University College London, UK.

John Lally (J)

Visiting Researcher, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; and the Royal College of Surgeons in Ireland.

Margaret Heslin (M)

Research Fellow and Honorary Lecturer, Kings' Health Economics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.

Brendon Stubbs (B)

NIHR Lecturer, Department of Psychological Medicine, Institute of Psychiatry, King's College London; and Head of Physiotherapy, Physiotherapy Department, South London and Maudsley NHS Foundation Trust, UK.

Stefania Bonaccorso (S)

Consultant Psychiatrist, C&I Foundation Trust; and Visiting Lecturer, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

Anna Kolliakou (A)

Clinical Informatics Interface and Network Lead, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

Oliver Howes (O)

Professor of Molecular Psychiatry, MRC London Institute for Medical Sciences; and Institute of Psychiatry, Psychology and Neuroscience, Kings College London; and the South London and Maudsley NHS Foundation Trust, UK.

David Taylor (D)

Director of Pharmacy and Pathology and Head of Pharmaceutical Sciences Clinical Academic Group, King's Health Partners, South London and Maudsley NHS Foundation Trust, UK.

Marta Di Forti (MD)

MRC Clinician Scientist, Department of Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; the South London and Maudsley NHS Foundation Trust, UK; and Department of Psychiatry, Experimental Biomedicine and Clinical Neuroscience (BIONEC), University of Palermo, Italy.

Anthony S David (AS)

Professor of Mental Health, Director and Sackler Chair, Institute of Mental Health, Division of Psychiatry, University College London, UK.

Robin M Murray (RM)

Professor of Psychiatric Research, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; the South London and Maudsley NHS Foundation Trust, UK; and Department of Psychiatry, Experimental Biomedicine and Clinical Neuroscience (BIONEC), University of Palermo, Italy.

Khalida Ismail (K)

Professor of Psychiatry and Medicine, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH